Chemotherapy With or Without Enoxaparin in Pancreatic Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2004
To evaluate the safety and efficacy of chemotherapy with or without enoxaparin. This study is powered to decrease the DVT/ VTE events rate from 10% to 3% with enoxaparin in the experimental arm. N=540pts, dropout-rate 15%, power 80 %, two sided, significant level 5%
Epistemonikos ID: e4edfd65475731943a8b3a4309a94ff694e1cb66
First added on: Jun 07, 2022